Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCyIF-1
- Development stage
- Preclinical
- Lead developer
- BioCytics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCyIF-1 (BioCytics Immune Fraction #1) is an autologous memory natural killer (NK) cell therapy being developed by BioCytics for the treatment of solid tumors. The therapy involves the ex-vivo expansion and adoptive transfer of autologous memory NK cells that recognize tumor cells through multiple innate immune mechanisms, including sensing Human Leukocyte Antigen (HLA) downregulation, stress-induced ligands (innate signals of cellular stress), and phosphoantigens. This approach leverages the intrinsic specificity of the patient's own immune system without the use of chimeric antigen receptors (CARs), utilizing a proprietary ex-vivo culture system designed for point-of-care collection, expansion, and formulation. As of late 2025, the program is in preclinical development with plans for first-in-human clinical trials in 2027.
- Other names
- autologous memory natural killer cellsautologous NK cells
Beyond the preview
Go deeper on BCyIF-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCyIF-1.